AB0798 PREVALENCE AND CLINICAL SPECTRUM OF CARDIAC INVOLVEMENT IN BEHÇET’S SYNDROME: A SINGLE CENTER RETROSPECTIVE STUDY

Background Behçet’s Syndrome (BS) is a systemic vasculitis, which main clinical features include mucocutaneous manifestations, pan-uveitis, non-deforming arthritis, thrombosis, central nervous system (CNS) and gastrointestinal (GI) involvement [1] . Despite being increasingly recognized as part of the spectrum in BS [2,3,4] , cardiac has not been systematically described. Objectives To investigate prevalence manifestation cohort patients. Methods Three hundred twelve patients were retrospectively studied. All fulfilled International Classification Criteria for [5] Demographic, clinical, therapeutic features, specific data on collected. Results Cardiac was observed 46 out 312 (13.2%). The mean age at diagnosis 43 years (SD ± 13.2). Mean duration before onset 5.35 6.86). Female to male ratio 1.42. Among with involvement, 37 (80.4%) displayed single manifestation, while 9 (19.5%) showed two or more events. related lesions included arrhythmias (n=12; 26%), pericarditis ischemic heart disease (n=7; 15%), acute myocarditis (n=5; 10.8%), valvular abnormalities (n=8; 17.3%), pulmonary hypertension (n=2; 4.3%) (Figure 1 ). Thirteen (28.2%) had classified “other”, patent foramen ovale, Takotsubo syndrome, amyloidosis, aortic root aneurysm After first event, remission manifestations achieved by all relapse occurred (19.5%), due recurrent (n=7), (n=1), arrhythmic (n=1). Overall are shown Table Muco-cutaneous present almost patients, specifically oral aftosis 45/46 (98%), genital 26/46 (56.5), skin 35/46 (76%). A significant proportion vascular (n=20; 43,4%), CNS 43.4%), GI (n=32; 69.5%). At time events 21/46 (45.6%) receiving corticosteroids, 16/46 (34.7%) colchicine, 13/46 traditional DMARD, 19/46 (41.3%) biologic DMARD (Table Conclusion Our study indicates that fairly common pointing need routine screening such involvement. As previously described [2] our suggests association between BS. Furthermore, we found presenting other major organ suggesting may reflect severe course. References [1]Bettiol Rheumatology (Oxford) 2020 [2]Geri Medicine (Baltimore) 2012 [3]Chen Clin Rheumatol 2019 [4]Kechida Adv 2018 [5]International Team Revision Disease J Eur Acad Dermatol Venereol 2014 Figure 1. Spectrum monocentric Demographic (46) N (%) 27 (58.6%) Age (mean SD) (± 13.2) Cardiovascular risk factors (% ) Smoking habit 7 (15.2%) Dyslipidemia 11 (24%) Hypertension 10 (21.7%) Diabetes 2 (4.3%) Clinical Oral 45 (98%) Genital 26 (56.5%) Ocular 12 (26%) Skin 35 (76%) Positive pathergy test Vascular 20 (43.4%) 32 (69.5%) Articular 33 (71.7%) HLA-B51 positivity 30 (65.2%) Treatment Corticosteroids 21 Colchicine 16 Traditional DMARDs 13 Biologic 19 Acknowledgements: NIL. Disclosure Interests None Declared.